These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 21325596)

  • 1. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.
    Quentin S; Cuccuini W; Ceccaldi R; Nibourel O; Pondarre C; Pagès MP; Vasquez N; Dubois d'Enghien C; Larghero J; Peffault de Latour R; Rocha V; Dalle JH; Schneider P; Michallet M; Michel G; Baruchel A; Sigaux F; Gluckman E; Leblanc T; Stoppa-Lyonnet D; Preudhomme C; Socié G; Soulier J
    Blood; 2011 Apr; 117(15):e161-70. PubMed ID: 21325596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia.
    Mehta PA; Harris RE; Davies SM; Kim MO; Mueller R; Lampkin B; Mo J; Myers K; Smolarek TA
    Cancer Genet Cytogenet; 2010 Dec; 203(2):180-6. PubMed ID: 21156231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A; Savva N; Mishkova O; Aleinikova OV
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
    Harada H; Harada Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Cytogenetic Approach to Characterize Novel and Cryptic Chromosome Abnormalities in Childhood Myeloid Malignances of Fanconi Anemia.
    Borges ML; Capela de Matos RR; Amaral BD; Soares-Ventura EM; Leite EP; Silva MO; Cornélio MT; Silva ML; Liehr T; Marques-Salles TD
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):e85-e91. PubMed ID: 28212262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fanconi Anemia patient with AML1 gene amplification and monosomy 7 in pre-transplant myelodysplasia (MDS) relapsing 7 years after successful allo-SCT.
    Ayas M; Walter C
    Bone Marrow Transplant; 2008 Oct; 42(8):555-7. PubMed ID: 18622412
    [No Abstract]   [Full Text] [Related]  

  • 9. IS THE AMPLIFICATION OF c-MYC, MLL AND RUNX1 GENES IN AML AND MDS PATIENTS WITH TRISOMY 8, 11 AND 21 A FACTOR FOR A CLONAL EVOLUTION IN THEIR KARYOTYPE?
    Angelova S; Spassov B; Nikolova V; Christov I; Tzvetkov N; Simeonova M
    Tsitol Genet; 2015; 49(3):25-32. PubMed ID: 26214902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
    Babushok DV; Bessler M
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 12. Chromosome abnormalities in bone marrow of Fanconi anemia patients.
    Berger R; Le Coniat M; Schaison G
    Cancer Genet Cytogenet; 1993 Jan; 65(1):47-50. PubMed ID: 8431915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
    Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
    PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fanconi anemia.
    Soulier J
    Hematology Am Soc Hematol Educ Program; 2011; 2011():492-7. PubMed ID: 22160080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
    Harada H; Harada Y; Kimura A
    Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel.
    Alvarez S; Cigudosa JC
    Hematol Oncol; 2005 Mar; 23(1):18-25. PubMed ID: 16142824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
    Venkatraj VS; Gaidano G; Auerbach AD
    Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.
    Dicker F; Haferlach C; Sundermann J; Wendland N; Weiss T; Kern W; Haferlach T; Schnittger S
    Leukemia; 2010 Aug; 24(8):1528-32. PubMed ID: 20520634
    [No Abstract]   [Full Text] [Related]  

  • 20. Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.
    Ceccaldi R; Briot D; Larghero J; Vasquez N; Dubois d'Enghien C; Chamousset D; Noguera ME; Waisfisz Q; Hermine O; Pondarre C; Leblanc T; Gluckman E; Joenje H; Stoppa-Lyonnet D; Socié G; Soulier J
    J Clin Invest; 2011 Jan; 121(1):184-94. PubMed ID: 21183791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.